scholarly journals Efficiency (advantages) of ramipril in arterial hypertension and diabetes mellitus from the point of view of evidence-based medicine

2020 ◽  
pp. 50-58
Author(s):  
M. V. Leonova
Keyword(s):  
Diabetes Mellitus ◽  
Arterial Hypertension ◽  
Evidence Based Medicine ◽  
Point Of View ◽  
Evidence Based ◽  
Based Medicine

scholarly journals Rehabilitation in acute stroke from the point of view of evidence-based medicine: possibilities of drug treatment

2019 ◽  
Vol 11 (3) ◽  
pp. 99-103
Author(s):  
A. A. Kulesh
Keyword(s):  
Ischemic Stroke ◽  
Drug Treatment ◽  
Acute Stroke ◽  
Evidence Based Medicine ◽  
Point Of View ◽  
Spatial Neglect ◽  
Evidence Based ◽  
Mirror Therapy ◽  
Upper Extremity Function ◽  
Based Medicine

The review highlights the fundamental principles of early rehabilitation in ischemic stroke, the benefits and risks of early and very early patient mobilization. It presents data on the efficiency of CIMT-kinesiotherapy and mirror therapy in restoring upper extremity function, as well as procedures for nonpharmacological correction of spatial neglect syndrome. The effect on the rehabilitation of concomitant Alzheimer's disease is analyzed. The areas of pharmacological potentiation of poststroke rehabilitation, the efficiency of cerebrolysin in particular, are considered.

scholarly journals Over-diagnosis and other crises facing evidence-based medicine

2014 ◽  
Vol 13 (3) ◽  
pp. 129-130
Author(s):  
Huw Llewelyn ◽  
Keyword(s):  
Evidence Based Medicine ◽  
Point Of View ◽  
Evidence Based ◽  
Raw Data ◽  
Acute Medicine ◽  
Coagulation Monitoring ◽  
Negative Results ◽  
Reduced Frequency ◽  
Low Threshold ◽  
Based Medicine

There is a crisis in ‘evidence-based medicine’ (EBM). Reviewers and meta-analysts have become aware that much of their work may be futile because some investigators only publish selected results that favour their own point of view. Such reviews can only be reliable if there is access to all the raw data or if everyone is compelled to publish ‘negative’ results too. This is proving difficult and controversial. The latest example is dabigatran, which was hailed as a safe advance that needs no coagulation monitoring. It seems that the reduced frequency of bleeding if there is coagulation monitoring was not reported. There is also widespread uncertainty about the thresholds for treatment. This has been highlighted in the ‘over-diagnosis campaign’ to address a concern that many patients are subjected to harm without much benefit. Many see the problem as one of vested interest e.g. where those who gain from supplying a treatment will tend to advocate a low threshold for treating whereas those who wish to reduce costs or effort prefer to set high thresholds. The evidence needs to support what is best for the patient and gathered by those who care for them e.g. acute medicine physicians.

scholarly journals Anti-D-immunoprophylaxis

2015 ◽  
Vol 64 (3) ◽  
pp. 52-57
Author(s):  
Nataliya Grigor’yevna Pavlova
Keyword(s):  
Evidence Based Medicine ◽  
Point Of View ◽  
European Countries ◽  
Evidence Based ◽  
Federal Programs ◽  
Foreign Countries ◽  
Economic Advisability ◽  
Based Medicine ◽  
Working Out

The working out and introducing of anti-D-immunoprofylaxis program in the time of pregnancy in foreign countries and Russia are discussed, effectiveness of its long-term using on the base of the federal programs in developed European countries and America is analyzed; necessity and economic advisability of its introducing on the base of the federal and municipal programs in Russia from the evidence-based medicine point of view are considered, indications and arguable points of the program are discussed.

Sign in / Sign up

Export Citation Format

Share Document